| 2011 | | Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C | 김영배, 정재연, 조성원 |
| 2007 | | Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. | 정재연, 조성원 |
| 2018 | | Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma | 김보현, 김순선, 김재근, 김진우, 김현지, 원제환, 이제희, 정재연, 조성원, 조효정 |
| 2013 | | Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. | 정재연, 조성원 |
| 2020 | | Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir | 김순선, 정재연 |
| 2022 | | Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study | 김봉완 |
| 2000 | | Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. | 김진홍, 조성원, 함기백 |
| 2021 | | Role of immune cells in patients with hepatitis b virus‐related hepatocellular carcinoma | 정재연, 조효정 |
| 2011 | | Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. | 김영배, 정재연, 조성원 |
| 2023 | | Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea | 김순선 |
| 2015 | | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. | 김순선, 신성재, 유병무, 정재연, 조성원, 조효정 |
| 2011 | | Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. | 김영배, 정재연, 조성원 |
